A5085208625- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Gastric Cancer Management and Outcomes
- Estrogen and related hormone effects
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Neutropenia and Cancer Infections
- Lung Cancer Research Studies
- Chemotherapy-related skin toxicity
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- MRI in cancer diagnosis
- Metastasis and carcinoma case studies
- Vascular Tumors and Angiosarcomas
- Chronic Lymphocytic Leukemia Research
- Esophageal and GI Pathology
- Breast Lesions and Carcinomas
- Advanced MRI Techniques and Applications
- Gastrointestinal Tumor Research and Treatment
Klinikum Klagenfurt
2018-2024
Medical University of Vienna
2009-2021
Comprehensive Cancer Center Vienna
2011-2021
In-Q-Tel
2015
Krankenhaus der Elisabethinen
2014
Vienna General Hospital
2000-2010
National Cancer Centre Japan
2007
Universitätszahnklinik Wien
2006
University of Vienna
2004-2005
University of Applied Sciences Kufstein
2005
Purpose In human epidermal growth factor 2 (HER-2)–positive advanced breast cancer, taxanes or vinorelbine plus trastuzumab are among the most widely applied options in first-line setting. We evaluated efficacy and tolerability of capecitabine after anthracycline docetaxel failure prior exposure. Patients Methods Forty consecutive patients were included. Capecitabine was administered at a dose 1,250 mg/m bid for 14 days 3-week cycles, with modifications if necessary. Trastuzumab every 3...
To develop a 3.0 Tesla breast imaging protocol that combines high temporal and spatial resolution three-dimensional MR sequences for quantitative time course morphologic analysis of lesions.Thirty-four patients were included in the study (age range, 31-82; mean age, 54.3). The was approved by Institutional Review Board written informed consent obtained from all patients. magnetic resonance included: coronal T1-weighted volume-interpolated-breathhold-examination sequence, focused on optimal...
Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain free survival (BMFS) of cancer subtypes treated between 1996 until 2010. measured as the interval from diagnosis extracranial BM. HER-2 status analysed by immunohistochemistry and reanalysed fluorescent situ hybridisation if a score 2+ gained. Oestrogen-receptor (ER) progesterone-receptor...
Trastuzumab-based therapy after diagnosis of brain metastases (BM) may improve survival due to prolonged systemic disease control. We investigated whether lapatinib yield additional benefit.Eighty patients with BM from HER2-positive breast cancer were identified. Karnofsky Performance Score (KPS) at least 70 was required. included a control group 37 treated before 2003, when continuation trastuzumab not yet recommended. Remainders received either or and (either concomitantly sequentially)...
The human epidermal growth factor receptor-2 gene (HER-2) encodes for a membrane-bound tyrosine kinase (Her-2), which is overexpressed in various cancers. Her-2-targeted therapy has recently been shown to be beneficial patients with advanced gastric cancer. Her-2 protein expression was investigated 341 esophageal carcinomas [152 squamous cell (SCC), 189 adenocarcinomas (AC)], 39 cases of Barrett mucosa, and 11 dysplasia. HER-2 amplification assessed by colorimetric in-situ hybridization....
Abstract Background Combining trastuzumab and chemotherapy is standard in her2/ neu overexpressing advanced breast cancer. It not established however, whether treatment should continue after the failure of one earlier combination. In this trial, we report our experience with continued beyond disease progression. Methods Fifty-four patients, median age 46 years, range 25–73 were included. We analysed for time to tumour progression (TTP) first, second line treatment, response rates overall...
The response of breast cancer patients to neoadjuvant chemotherapy (NCT) is highly heterogeneous, and reliable predictive instruments remain be defined. High-mobility group box-1 (HMGB-1) protein a cell death marker, which easily detectable in plasma. We hypothesized that the initial dose NCT with epirubicin/docetaxel induces changes plasma HMGB-1 could allow for an early prediction therapy.First, we analysed whether releases from HCC1143 cells vitro. Thereafter, levels before 1-4 days after...
Despite the widespread use of neoadjuvant chemotherapy in breast cancer patients, prediction individual response to treatment remains an unsolved clinical problem. Particularly, administration inefficient chemotherapeutic regimen should be avoided. Therefore, a better understanding molecular mechanisms underlying is particular interest. Aim present study was test whether with epirubicin/docetaxel induces early changes plasma proteome patients and such correlate therapy. Plasma samples 25...
Spatially resolved quantification of platinum distribution in patients that exhibited extravasation was feasible up to 4 weeks upon drug application.
In advanced breast cancer, multiple sequential lines of treatments are frequently applied. Pegylated liposomal doxorubicin (PLD) has a favourable toxicity profile and can be used in first or higher therapy. PLD demonstrated response activity even after prior anthracycline exposure. 129 consecutive patients with whom the majority had been massively pretreated, received as monotherapy within licensed approval, for which efficacy toxicities were documented. routine therapy setting, was...
Abstract Background Some 10–15 per cent of patients with oesophageal cancer overexpress human epidermal growth factor receptor (HER) 2 at the primary tumour site, leading to hope that specific targeted systemic therapy might favourably influence clinical and subclinical disease locoregional distant sites. This approach is based on characteristics, without knowledge expression patterns metastatic In cancer, concordance between HER-2 status other sites unknown. Methods The tumours...
Capecitabine is a novel fluoropyrimidine carbamate which selectively activated after oral administration to 5-fluorouracil (5-FU) by sequential triple enzyme pathway in liver and tumor cells. The cytotoxic activity of the metabolized 5-FU depends on thymidylate synthase (TS) inhibition, leading defective DNA synthesis. has shown promising all types sensitive therefore investigated many clinical trials. Since we observed an increase mean corpuscular volume (MCV) red blood cells under therapy...